CoChat

Access to Patient-Level Data from GlaxoSmithKline Clinical Trials

Open access
Nisen, Perry, Rockhold, Frank · 2013 · New England Journal of Medicine
Cited by 120

The DOI matches its Crossref record.

Abstract

Efforts are under way to increase the transparency of clinical trial data.Among the efforts are those being undertaken at GlaxoSmithKline, where we have recently made a commitment to provide access to deidentified patient-level data.We are taking this step because it is the right thing to do, both scientifically and for society, and it is in line with our company's commitment to transparency in clinical trial reporting.As of May 2013, investigators are able to request access to deidentified patient-level data from a subset of GlaxoSmithKline-sponsored clinical trials.We expect that research teams requesting data will have sufficient statistical and data-management expertise to evaluate these data sets, and we call for standards in analysis to be defined by the scientific community.This article describes the approach we are adopting and answers some of the most common questions we have received since our announcement of this policy.Which GlaxoSmithKline studies will be available?The GlaxoSmithKline Clinical Study Requests website (https://clinicalstudydata.gsk.com)lists studies available as of May 7, 2013, when the website was launched.These studies are also listed in Section 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.The list includes clinical studies of medicines that have been approved for specific indications (anywhere in the world) and medicines that have been terminated from development.Manuscripts describing the results of a study -whether they are perceived as positive or negative -are submitted for publication within 18 to 24 months after the last study visit by the last participant enrolled.A study is added to the list once the primary manuscript describing the results has been accepted for publication.Studies that have not been accepted for publication, as well as those that are not submitted or are no longer being submitted for publication, are also available.1.Data Protection Working Party.Opinion 4/2007 on the concept of personal data (http://ec.europa.eu/justice/policies

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmsr1302541

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 120

Metadata

Authors
Nisen, P., & Rockhold, F.
Venue
New England Journal of Medicine
Published
2013-08
Volume
369
Issue
5
Pages
475-478
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2076925836
Cited by
120
References
0
FWCI
23.55
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Access to Patient-Level Data from GlaxoSmithKline Clinical Trials. https://app.cochat.ai/papers/10.1056/nejmsr1302541
The paper
Nisen, P., & Rockhold, F. (2013). Access to Patient-Level Data from GlaxoSmithKline Clinical Trials. New England Journal of Medicine. https://doi.org/10.1056/nejmsr1302541

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.